Taylor & Francis Group
Browse

Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS. Infographic

Download (150.85 kB)
Version 2 2023-03-29, 09:21
Version 1 2023-03-29, 08:29
figure
posted on 2023-03-29, 09:21 authored by Patrick Schöffski, Mehdi Lahmar, Anthony Lucarelli, Robert G Maki

Infographic

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    phase II/III trialMDM2–p53 antagonistdoxorubicindedifferentiated liposarcomaBI 907828

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC